Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study - Subbiah, V; Hu, MI; Wirth, LJ (Lancet Diabetes Endocrinol, 2021)
et al.